Last reviewed · How we verify
NCT05347797
Clinical Study Testing DNA Extracted From Tumour Tissue Biopsy Samples, Using the Therascreen® KRAS RGQ PCR Kit
NA trial testing therascreen® KRAS RGQ PCR Kit in Non-small Cell Lung Cancer in 495 participants. Completed in 22 April 2021.
22 April 2021
Quick facts
| Lead sponsor | QIAGEN Gaithersburg, Inc |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 495 |
| Start date | 13 March 2020 |
| Primary completion | 22 April 2021 |
| Estimated completion | 22 April 2021 |
| Sites | 1 location across United Kingdom |
Drugs / interventions tested
- therascreen® KRAS RGQ PCR Kit
Conditions studied
- Non-small Cell Lung Cancer — all drugs for Non-small Cell Lung Cancer →
Sponsor
QIAGEN Gaithersburg, Inc — full company profile →
Who can join
Eligibility, any sex, with Non-small Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
An interventional, prospective study. It is estimated that up to 800 patient tissue samples (from approximately 650 patients enrolled at approximately 300 clinical trial sites), will be obtained as part of enrolment into Phase 3 of Clinical Study (Protocol No. 20190009), for testing using the therascreen® KRAS RGQ PCR Kit (KRAS Kit).
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05347797
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of therascreen® KRAS RGQ PCR Kit
Trials testing the same drug.
- NCT06645236 — DHF-20-1839-2: Clinical Performance Study Protocol for Therascreen® KRAS RGQ PCR Kit · NA · recruiting
- NCT05347745 — Therascreen® KRAS RGQ PCR Kit · NA · completed
- NCT05360225 — Testing of DNA Extracted From Tumor Tissue Biopsy Samples Using Therascreen KRAS RGQ PCR Kit · completed
- NCT05348187 — Clinical Performance Study Protocol for Therascreen® KRAS RGQ PCR Kit · NA · completed
Other recruiting trials for Non-small Cell Lung Cancer
Currently open trials in the same condition.
- NCT07431827 — MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013) · Phase 3 · recruiting
- NCT05987956 — Pharmacogenomics IND EXEMPT SNP Clinical Trial - Alectinib and Single Nucleotide Polymorphisms · Phase 2, PHASE3 · active not recruiting
- NCT07195695 — Beamion LUNG-3: A Study to Test Whether Zongertinib Helps People With Surgically Removed, Non-small Cell Lung Cancer Wit · Phase 3 · recruiting
- NCT06686771 — Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer · Phase 3 · recruiting
- NCT06477055 — The Recurrence Gene Profiles of Adjuvant Osimertinib Therapy in Resected Non-Small-Cell Lung Cancer · recruiting
Other QIAGEN Gaithersburg, Inc trials
Trials by the same sponsor.
- NCT06360757 — Clinical Evaluation of the NeuMoDx SARS-CoV-2 Assay (COVID-19) · terminated
- NCT06645236 — DHF-20-1839-2: Clinical Performance Study Protocol for Therascreen® KRAS RGQ PCR Kit · NA · recruiting
- NCT05305534 — QIAstat-Dx® BCID Plus AMR Panels Clinical Performance Study · completed
- NCT05733559 — QIAstat-Dx® Respiratory Panel Plus (RPP) Clinical Performance Study · completed
- NCT06681025 — Clinical Performance Evaluation of the NeuMoDx™ EBV Quant Assay 2.0 in Immunocompromised Transplant Patients · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05347797 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by QIAGEN Gaithersburg, Inc
- Last refreshed: 4 November 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05347797.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing